Diapride M contains Glimepiride + Metformin. Metformin and Sulfonylureas belongs to the class of combinations of oral blood glucose lowering drugs. Used in the treatment of type 2 diabetes mellitus. It may be used along with Insulin or other medicines in order to achieve better control over the blood sugar levels.
Diapride M is product off Microlabs. Micro Labs is a multi-faceted organization. The glittering stars of the company are 14 oral formulation plants including an injectable unit; a bulk drug facility, offices located overseas, and a strong distribution network. Our marketing efforts span into 20 divisions, with each division specialized to cater to various therapeutic segments.
The company today, has 20 marketing divisions catering to leading therapeutic segments such as Cardiology, Diabetology, Pain management, Dermatology, Veterinary, Neurology, etc.
Insulin is a hormone made by your pancreas that acts like a key to let blood sugar into the cells in your body for use as energy. If you have type 2 diabetes, cells don’t respond normally to insulin; this is called insulin resistance. Your pancreas makes more insulin to try to get cells to respond. Eventually your pancreas can’t keep up, and your blood sugar rises, setting the stage for prediabetes and type 2 diabetes. High blood sugar is damaging to the body and can cause other serious health problems, such as heart disease, vision loss, and kidney disease.
People are at risk for developing type 2 diabetes if they have prediabetes, are overweight, are 45 years or older, have a parent, brother, or sister with type 2 diabetes, are less physically active or had gestational diabetes (diabetes during pregnancy). It can be prevented or delayed with simple, proven lifestyle changes such as losing weight if you’re overweight, eating healthier, and getting regular physical activity.
Concomitant administration with propranolol increases Cmax, AUC, and T1/2 of glimepiride. Aspirin increases the mean AUC of glimepiride. Furosemide increases the Cmax of metformin.
Potentially Fatal: NSAIDS, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid, MAOs, and beta blockers potentiate the hypoglycemic action of glimepiride.
Mechanism of Action
Glimepiride stimulates the insulin release from functioning pancreatic β-cells and inhibits gluconeogenesis at hepatic cells. It also increases insulin sensitivity at peripheral target sites. Metformin decreases hepatic gluconeogenesis, decreases intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilisation).